Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Assets | |||||
Current Assets | |||||
Cash & Cash Equivalents | 2,853,000 | 416,000 | 1,944,000 | 1,786,000 | 1,121,000 |
Marketable Securities | 9,837,000 | 22,316,000 | 29,125,000 | 10,437,000 | 8,525,000 |
Receivables | 11,177,000 | 10,952,000 | 11,479,000 | 7,913,000 | 6,772,000 |
Inventories | 10,189,000 | 8,981,000 | 9,059,000 | 8,020,000 | 7,068,000 |
Income taxes - deferred | N/A | N/A | 4,266,000 | 3,264,000 | 2,736,000 |
Other current assets | 9,277,000 | 8,594,000 | 3,820,000 | 3,647,000 | 6,581,000 |
TOTAL | $43,333,000 | $51,259,000 | $59,693,000 | $35,067,000 | $32,803,000 |
Non-Current Assets | |||||
PPE Net | 18,940,000 | 16,274,000 | 14,882,000 | 13,745,000 | 12,969,000 |
Investments And Advances | 15,368,000 | 15,069,000 | 21,526,000 | 20,262,000 | 20,147,000 |
Intangibles | 132,683,000 | 94,745,000 | 74,354,000 | 77,893,000 | 82,138,000 |
Other Non-Current Assets | 16,177,000 | 19,856,000 | 11,020,000 | 7,262,000 | 19,537,000 |
TOTAL | $183,168,000 | $145,944,000 | $121,782,000 | $119,162,000 | $134,791,000 |
Total Assets | $226,501,000 | $197,205,000 | $181,476,000 | $154,229,000 | $167,594,000 |
Liabilities | |||||
Current Liabilities | |||||
Short Term Debt | 10,350,000 | 2,945,000 | 2,241,000 | 2,703,000 | 16,195,000 |
Accounts payable and accrued liabilities | 6,710,000 | 6,809,000 | 5,578,000 | 4,283,000 | 3,887,000 |
Accrued Expenses | 2,776,000 | 3,407,000 | 3,332,000 | 3,049,000 | 2,390,000 |
Other current liabilities | 20,537,000 | 22,568,000 | 24,939,000 | 11,561,000 | 9,334,000 |
TOTAL | $47,794,000 | $42,138,000 | $42,671,000 | $25,920,000 | $37,304,000 |
Non-Current Liabilities | |||||
Long Term Debt | 61,538,000 | 32,884,000 | 36,195,000 | 37,133,000 | 35,955,000 |
Deferred Revenues | 2,700,000 | 2,520,000 | 3,067,000 | 1,113,000 | N/A |
aiOther Non-Current Liabilities | 27,201,000 | 25,207,000 | 24,753,000 | 23,604,000 | 25,208,000 |
TOTAL | $89,418,000 | $59,149,000 | $61,342,000 | $64,836,000 | $66,844,000 |
Total Liabilities | $137,213,000 | $101,288,000 | $104,013,000 | $90,756,000 | $104,148,000 |
Shareholders' Equity | |||||
Shares Outstanding, K | 5,646,778 | 5,619,075 | 5,623,347 | 5,577,630 | 5,547,639 |
Common Shares | 478,000 | 476,000 | 473,000 | 470,000 | 468,000 |
Retained earnings | 118,353,000 | 125,656,000 | 103,394,000 | 90,392,000 | 97,670,000 |
Other shareholders' equity | -7,687,000 | -8,049,000 | -5,635,000 | -5,075,000 | -11,318,000 |
TOTAL | $89,288,000 | $95,916,000 | $77,462,000 | $63,473,000 | $63,447,000 |
Total Liabilities And Equity | $226,501,000 | $197,204,000 | $181,475,000 | $154,229,000 | $167,595,000 |